SS-31
Also known as Elamipretide
Studied for: mitochondrial membrane research
SS-31, also known as elamipretide, is studied for its affinity for the inner mitochondrial membrane. Research focuses on cardiolipin, a phospholipid central to mitochondrial efficiency.
Last reviewed September 26, 2026
How it is thought to work
Research describes SS-31 as concentrating in the inner mitochondrial membrane and interacting with cardiolipin, studied for effects on electron-transport efficiency and oxidative stress.
- Cardiolipin AffinityStudied for selective binding to a phospholipid that shapes the structure of the inner mitochondrial membrane.
- Redox BalanceExplored for effects on electron-transport efficiency and the oxidative by-products of energy production.
- Route studied
- Subcutaneous
- Research status
- Approved analog
Elamipretide (SS-31) has been evaluated in a phase 3 randomized clinical trial in primary mitochondrial myopathy, and a 2026 review titled 'Elamipretide: First Approval' reports its first regulatory approval.
Research
What the research covers
What research examines
- Cardiolipin binding in the inner mitochondrial membrane
- Electron-transport efficiency and oxidative stress
- Primary mitochondrial myopathy in a phase 3 clinical trial
- Mitochondrial dysfunction in heart failure research
- Synaptic and memory impairment in mouse models of inflammation
- Cardiomyocyte hypoxia/reoxygenation injury in cell models
Reported effects in studies
- Safety was an evaluated endpoint in the MMPOWER-3 phase 3 trial in primary mitochondrial myopathy
- Specific adverse events are not summarized in the cited study titles
- Much of the mechanistic evidence comes from animal and cell studies
Studied range
What research protocols have used
Research protocols have used 1–10 mg per administration, 3 times per week (morning), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- NAD+NAD+ is a coenzyme central to how cells convert fuel into usable energy. Research examines its role in redox reactions, mitochondrial output, and the repair pathways associated with biological aging.Read profile$99
- EpithalonEpithalon is a synthetic tetrapeptide studied for its potential role in cellular longevity and biological-rhythm pathways. Research explores its relationship with telomere biology and pineal signaling.Read profile$39
- TesamorelinTesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.Read profile$99
- CJC-1295CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.Read profile$119
Studies
Cited research
- Elamipretide: First Approval.
Drugs · 2026 · Review · PMID 41335372
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Neurology · 2023 · RCT · PMID 37268435
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
International journal of molecular sciences · 2025 · Review · PMID 39940712
- Targeting mitochondrial dysfunction with elamipretide.
Heart failure reviews · 2022 · Review · PMID 35037146
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.
Journal of neuroinflammation · 2019 · PMID 31747905
FAQ
Questions about SS-31
SS-31, also known as elamipretide, is a peptide studied for its affinity for the inner mitochondrial membrane. Research centers on its interaction with cardiolipin, a phospholipid central to mitochondrial structure and efficiency. It has been investigated in preclinical models and in human clinical trials, including a phase 3 trial in primary mitochondrial myopathy, and a 2026 review reports its first regulatory approval.
Research describes SS-31 as concentrating in the inner mitochondrial membrane and interacting with cardiolipin, a phospholipid that shapes the membrane's structure. Through this interaction, it has been studied for effects on electron-transport efficiency and on the oxidative by-products generated during cellular energy production. These mechanistic descriptions come largely from laboratory and animal research and are summarized in published reviews of its structure and mechanism of action.
Studies have examined SS-31 in several settings. A phase 3 randomized trial, MMPOWER-3, assessed its efficacy and safety in primary mitochondrial myopathy. Reviews discuss targeting mitochondrial dysfunction in heart failure. Mouse research examined mitochondrial dysfunction, synaptic function and memory impairment induced by lipopolysaccharide, and cell studies have explored mitochondria-targeted formulations in cardiomyocyte hypoxia/reoxygenation injury. Findings vary by model and should be interpreted within each study's design.
Safety was formally assessed as an endpoint in the MMPOWER-3 phase 3 trial in individuals with primary mitochondrial myopathy, and regulatory approval implies a safety review for at least one indication. However, specific adverse events are not summarized in the cited study titles, and much of the mechanistic literature comes from animal and cell models. Researchers should consult the full clinical publications for detailed safety findings.
Research protocols have used 1–10 mg per administration by the subcutaneous route, 3 times per week in the morning, in 8-week blocks followed by 4 weeks off. These figures describe protocols reported in research settings and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. SS-31 is supplied for laboratory research use only.
Ask about SS-31
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- SS-31 vs MOTS-cSS-31, also known as elamipretide, and MOTS-c are both peptides studied in mitochondrial and longevity research, but they are described as acting in different ways. SS-31 is researched for concentrating in the inner mitochondrial membrane and interacting with cardiolipin, a phospholipid that shapes membrane structure. Studies have examined its effects on electron-transport efficiency and oxidative stress. MOTS-c is a peptide encoded in mitochondrial DNA and is studied as a signal that translocates to the nucleus under metabolic stress, with research focused on AMPK-associated pathways. SS-31 has been evaluated in a phase 3 trial in primary mitochondrial myopathy and in heart failure research. MOTS-c research, mainly in animal and cell models, has examined obesity, insulin resistance, bone metabolism and islet cell senescence.